As a result of its arrangement with Sanofi, Novavax is a fundamentally different company than it was a month ago. Read More

Microsoft's founder has made a number of prescient stock market calls lately. Here's how you can profit from his next one. Read More

Last week's suspension of a COVID-19 vaccine triggered a ripple effect that caused call option premiums to spike for other vaccine producers. Read More

When viewed through the prism of monetary policy, the recent behavior of Bitcoin makes perfect sense. Read More

Over the past three months, Novavax has lost nearly half its value. That's about to change, and here is how you can profit. Read More

Mega-cap stocks have dominated the pandemic-era rally, but as the market leaders stumble, undervalued smaller fry offer the best growth potential. Read More

For companies that have seen their share prices soar, soon may be the time to use that stock as currency to buy other businesses. Read More

The trade we recommended for Novavax two months ago racked up a 500% gain. Now, we suggest a different strategy to profit from its extreme volatility. Read More

The pandemic has sown confusion among investors. In this interview, one of our experts provides clarity. Read More

Novavax is up nearly tenfold this year, but it's not too late to profit from the outcome of its COVID-19 vaccine trial. Read More